



transplantation originating from embryonic, fetal, or adult stem cell lineages, the era of large-scale clinical trials will be increasingly challenged as precision medicine that tailors therapy to the individual's genome and disease profile enters the clinic.

SUGGESTED READINGS

Cheng H, Force T: Why do kinase inhibitors cause cardiotoxicity and what can be done about it? *Prog Cardiovasc Dis* 53:114–120, 2010.

Collins FS, Green ED, Guttmacher AE: A vision for the future of genomics research, *Nature* 422:835–847, 2003.

Evans WE, McLeod HL: Pharmacogenomics: drug disposition, drug targets, and side effects, *N Engl J Med* 348:538–549, 2003.

Kim H, Kim JS: A guide to genome engineering with programmable nucleases, *Nat Rev Genet* 15:321–334, 2014.

Orlando G, Wood KJ, Stratta RJ, et al: Regenerative medicine and organ transplantation: past, present, and future, *Transplantation* 91:1310–1317, 2011.

Willard HF, Ginsburg GS, editors: *Genomic and personalized medicine*, New York, 2009, Elsevier.

Zamore PD, Haley B: Ribo-gnome: the big world of small RNAs, *Science* 309:1519–1524, 2005.